D
Dongkook Pharmaceutical Co Ltd
KOSDAQ:086450
Dongkook Pharmaceutical Co Ltd
KOSDAQ:086450
Price:
16 710
KRW
2.26%
Market Closed
Market Cap:
734.6B
KRW
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
Dongkook Pharmaceutical Co Ltd
16710
+370 (+2.26%)
| 52 Week Range |
15 680
19 470
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Dongkook Pharmaceutical Co Ltd
Balance Sheet
Balance Sheet Decomposition
Dongkook Pharmaceutical Co Ltd
Dongkook Pharmaceutical Co Ltd
| Current Assets | 481.2B |
| Cash & Short-Term Investments | 87.2B |
| Receivables | 214.9B |
| Other Current Assets | 179.2B |
| Non-Current Assets | 440B |
| Long-Term Investments | 128.8B |
| PP&E | 281.3B |
| Intangibles | 19.1B |
| Other Non-Current Assets | 10.7B |
| Current Liabilities | 225.4B |
| Accounts Payable | 92.7B |
| Accrued Liabilities | 7.6B |
| Short-Term Debt | 43.3B |
| Other Current Liabilities | 81.8B |
| Non-Current Liabilities | 118.2B |
| Long-Term Debt | 28.4B |
| Other Non-Current Liabilities | 89.8B |
Balance Sheet
Dongkook Pharmaceutical Co Ltd
Dongkook Pharmaceutical Co Ltd
Currency: KRW
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
26 414
|
37 033
|
56 363
|
63 132
|
61 802
|
70 260
|
54 537
|
85 444
|
73 693
|
60 552
|
|
| Cash Equivalents |
26 414
|
37 033
|
56 363
|
63 132
|
61 802
|
70 260
|
54 537
|
85 444
|
73 693
|
60 552
|
|
| Short-Term Investments |
22 889
|
26 486
|
32 763
|
39 248
|
54 611
|
82 033
|
119 649
|
83 486
|
30 261
|
33 158
|
|
| Total Receivables |
88 551
|
95 599
|
95 256
|
111 827
|
114 177
|
117 115
|
136 983
|
139 496
|
151 600
|
179 061
|
|
| Accounts Receivables |
81 997
|
87 790
|
88 180
|
102 428
|
101 677
|
105 734
|
123 489
|
124 926
|
134 407
|
162 003
|
|
| Other Receivables |
6 554
|
7 809
|
7 076
|
9 399
|
12 500
|
11 381
|
13 494
|
14 570
|
17 193
|
17 057
|
|
| Inventory |
31 467
|
32 522
|
45 243
|
50 703
|
63 511
|
60 867
|
79 048
|
102 591
|
120 152
|
138 343
|
|
| Other Current Assets |
3 842
|
3 539
|
4 368
|
6 276
|
6 327
|
8 747
|
8 545
|
9 210
|
9 615
|
8 083
|
|
| Total Current Assets |
173 164
|
195 179
|
233 994
|
271 186
|
300 428
|
339 022
|
398 763
|
420 226
|
385 321
|
419 197
|
|
| PP&E Net |
53 398
|
56 936
|
62 788
|
69 428
|
140 740
|
158 074
|
194 967
|
234 941
|
263 355
|
272 705
|
|
| PP&E Gross |
53 398
|
56 936
|
62 788
|
69 428
|
140 740
|
158 074
|
194 967
|
234 941
|
263 355
|
272 705
|
|
| Accumulated Depreciation |
50 735
|
56 112
|
59 071
|
80 083
|
87 570
|
99 851
|
114 076
|
127 464
|
143 986
|
162 292
|
|
| Intangible Assets |
3 971
|
4 197
|
4 230
|
4 326
|
4 359
|
4 244
|
7 299
|
6 916
|
10 873
|
16 162
|
|
| Goodwill |
1 053
|
1 053
|
1 053
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
100
|
100
|
2 159
|
2 094
|
2 094
|
638
|
6 000
|
6 006
|
6 003
|
6 003
|
|
| Long-Term Investments |
8 884
|
13 130
|
15 711
|
21 462
|
28 515
|
36 360
|
48 242
|
72 219
|
88 735
|
112 636
|
|
| Other Long-Term Assets |
3 597
|
4 203
|
5 163
|
4 812
|
4 109
|
6 045
|
7 893
|
9 768
|
14 042
|
12 832
|
|
| Other Assets |
1 053
|
1 053
|
1 053
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
244 166
N/A
|
274 799
+13%
|
325 098
+18%
|
373 308
+15%
|
480 245
+29%
|
544 384
+13%
|
663 165
+22%
|
750 076
+13%
|
768 330
+2%
|
839 535
+9%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
17 141
|
18 108
|
21 048
|
20 263
|
18 056
|
17 057
|
26 523
|
29 171
|
33 405
|
62 069
|
|
| Accrued Liabilities |
3 392
|
3 884
|
3 471
|
4 330
|
4 046
|
4 776
|
5 264
|
6 071
|
5 957
|
6 877
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
15 166
|
15 018
|
13 854
|
82 191
|
36 954
|
48 228
|
|
| Current Portion of Long-Term Debt |
4 492
|
6 963
|
5 136
|
9 515
|
0
|
2 070
|
22 486
|
24 375
|
26 979
|
36 300
|
|
| Other Current Liabilities |
27 748
|
29 879
|
43 233
|
46 074
|
55 099
|
71 089
|
96 768
|
100 793
|
95 243
|
77 679
|
|
| Total Current Liabilities |
52 773
|
58 834
|
72 888
|
80 182
|
92 367
|
110 011
|
164 895
|
242 601
|
198 539
|
231 153
|
|
| Long-Term Debt |
1 603
|
1 485
|
482
|
360
|
40 120
|
43 199
|
52 115
|
13 687
|
27 449
|
20 219
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
3 288
|
5 765
|
4 806
|
4 846
|
|
| Minority Interest |
256
|
998
|
1 022
|
15 556
|
18 589
|
22 545
|
24 438
|
27 079
|
29 125
|
31 480
|
|
| Other Liabilities |
13 226
|
13 866
|
13 391
|
13 271
|
16 146
|
5 754
|
7 061
|
6 378
|
6 471
|
7 144
|
|
| Total Liabilities |
67 857
N/A
|
75 182
+11%
|
87 783
+17%
|
109 369
+25%
|
167 222
+53%
|
181 509
+9%
|
251 797
+39%
|
295 510
+17%
|
266 391
-10%
|
294 841
+11%
|
|
| Equity | |||||||||||
| Common Stock |
22 230
|
22 230
|
22 230
|
22 230
|
22 615
|
22 615
|
22 615
|
22 615
|
22 615
|
22 615
|
|
| Retained Earnings |
142 923
|
166 385
|
203 892
|
239 583
|
278 409
|
328 380
|
376 729
|
419 761
|
467 179
|
507 318
|
|
| Additional Paid In Capital |
12 057
|
12 057
|
12 057
|
3 286
|
13 022
|
12 903
|
13 047
|
13 213
|
13 042
|
15 566
|
|
| Unrealized Security Profit/Loss |
854
|
838
|
1 029
|
733
|
870
|
870
|
870
|
870
|
870
|
870
|
|
| Treasury Stock |
3 000
|
3 138
|
3 138
|
3 138
|
3 138
|
3 138
|
3 138
|
3 138
|
3 095
|
3 053
|
|
| Other Equity |
1 245
|
1 245
|
1 245
|
1 245
|
1 245
|
1 245
|
1 245
|
1 245
|
1 329
|
1 379
|
|
| Total Equity |
176 309
N/A
|
199 617
+13%
|
237 315
+19%
|
263 939
+11%
|
313 023
+19%
|
362 874
+16%
|
411 368
+13%
|
454 566
+11%
|
501 939
+10%
|
544 694
+9%
|
|
| Total Liabilities & Equity |
244 166
N/A
|
274 799
+13%
|
325 098
+18%
|
373 308
+15%
|
480 245
+29%
|
544 384
+13%
|
663 165
+22%
|
750 076
+13%
|
768 330
+2%
|
839 535
+9%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
44
|
44
|
44
|
44
|
44
|
44
|
44
|
44
|
44
|
44
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
